1
|
Evin C, Just PA, Borghese B, Fabiano E, Bennani S, Canny E, Marisa L, Derive N, Laurent-Puig P, Alexandre J, Durdux C. Adenoid cystic carcinoma of Bartholin's gland, a case report with genomic data and literature review. Cancer Radiother 2023:S1278-3218(23)00008-2. [PMID: 36759241 DOI: 10.1016/j.canrad.2023.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 01/16/2023] [Accepted: 01/18/2023] [Indexed: 02/10/2023]
Abstract
Adenoid cystic carcinoma of the Bartholin's gland (ACCBG) is a rare, slowly but aggressive malignancy. We reported the case of a 31-year-old woman who was treated by local excision and then hemi-vulvectomy, with positive margins and perineural invasion. Radiation therapy (RT) was then performed delivering 45Gy in 25 fractions in bilateral inguinal lymph nodes and 64.8Gy in 36 fractions on the vulvar area. After 30 months, there was no local relapse (LR) but the patient presented a histologically documented lung recurrence. Genomic profiling of the tumor showed a MYB-NFIB fusion transcript and a somatic mutation of PLCG1. A treatment by Lenvatinib was started. We conducted a literature review of 100 published cases. Patients were mainly treated by radical vulvectomy (30%), hemi-vulvectomy (17%), wide or local excision (21% and 24%, respectively) or other. Forty-four percent of patients received postoperative RT, more frequently in case of positive margin (71.9% versus 29.5%). RT may reduce the risk of LR regardless of margin status, with 15.4% vs. 41.9% of LR with or without RT, respectively, in patients with negative margins, and 13% vs. 33.3% of LR with or without RT, respectively, in patients with positive margins. The risk of relapse of any type was 40.9% in patients who received adjuvant RT vs. 48.2% in patients who did not. Median time to relapse was 24 months (range 6-156 months). The most frequent metastatic sites were lung (76.7%) and bone (26.7%). Optimal treatment for ACCBG is still not clearly defined but pooling the data from published case report help us better understand this rare disease and help in the therapeutic decision.
Collapse
Affiliation(s)
- C Evin
- Service d'oncologie radiothérapie, université Paris-Cité, centre, hôpital européen Georges-Pompidou, AP-HP, Paris, France.
| | - P-A Just
- Service de pathologie, université Paris-Cité, centre, hôpital Cochin, AP-HP, Paris, France
| | - B Borghese
- Service de chirurgie et cancérologie gynécologique, médecine de la reproduction, université Paris-Cité, centre, hôpital Cochin, AP-HP, Paris, France
| | - E Fabiano
- Service d'oncologie radiothérapie, université Paris-Cité, centre, hôpital européen Georges-Pompidou, AP-HP, Paris, France
| | - S Bennani
- Service de radiologie A, université Paris-Cité, centre, hôpital Cochin, AP-HP, Paris, France
| | - E Canny
- Service de chirurgie thoracique, université Paris-Cité, centre, hôpital Cochin, AP-HP, Paris, France
| | - L Marisa
- Laboratoire de biologie médicale multisites SeqOIA, Paris, France
| | - N Derive
- Laboratoire de biologie médicale multisites SeqOIA, Paris, France
| | - P Laurent-Puig
- Laboratoire de biologie médicale multisites SeqOIA, Paris, France; Institut du cancer Paris CARPEM, centre, hôpital Européen Georges Pompidou, AP-HP, 75000 Paris, France
| | - J Alexandre
- Service d'oncologie médicale, université Paris-Cité, centre, hôpital Cochin, AP-HP, Paris, France
| | - C Durdux
- Service d'oncologie radiothérapie, université Paris-Cité, centre, hôpital européen Georges-Pompidou, AP-HP, Paris, France
| |
Collapse
|
2
|
Le Roy C, Vernerey D, Evin C, Richard S, Crespel C, Samaille T, Le Tourneau C, Huguet F. Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Oncol (R Coll Radiol) 2022; 34:e473-e481. [PMID: 36207237 DOI: 10.1016/j.clon.2022.09.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 07/13/2022] [Accepted: 09/14/2022] [Indexed: 01/31/2023]
Abstract
AIMS The EXTREME regimen is the standard for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). However, many patients have a poor performance status and/or comorbidities, making them unfit for this regimen. We have treated them with carboplatin and cetuximab (simplified EXTREME regimen) since 2007. Our aim was to assess the efficacy and tolerance of this regimen in this frail population. MATERIALS AND METHODS A retrospective chart review of all patients treated with the simplified EXTREME regimen for recurrent and/or metastatic HNSCC in three academic hospitals between 2007 and 2017 was carried out. The primary end point was overall survival. Secondary end points were progression-free survival (PFS), overall response rate (ORR) and toxicity. RESULTS One hundred and three patients were included. The median age was 63 years, 40% had performance status 2-3. The median follow-up was 30.2 months. The median overall survival and PFS were 7.2 and 3.7 months, respectively. The median overall survival was 10.1 months in patients with performance status 0-1 versus 4.6 months in patients with performance status 2-3 (P = 0.01). ORR was 39%. Acute grade 3-4 haematological and non-haematological toxicity rates were 25.2% and 27.2%, respectively. Patients with grade 1 or more skin toxicity had a higher ORR (hazard ratio = 3.44; P = 0.03), a prolonged overall survival (hazard ratio = 0.37; P < 0.0001) and PFS (hazard ratio = 0.29; P < 0.0001). During treatment, 29% of patients had pain reduction, 13.5% had weight gain and 17.2% had an improvement in performance status. CONCLUSIONS This is the largest cohort of patients treated with simplified EXTREME for HNSCC. It was well tolerated, with a high ORR. Interestingly, skin toxicity correlated with treatment efficacy.
Collapse
Affiliation(s)
- C Le Roy
- Department of Radiation Oncology, Tenon Hospital, AP-HP, Sorbonne Université, Paris, France
| | - D Vernerey
- Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, INSERM UMR 1098, Besançon, France
| | - C Evin
- Department of Radiation Oncology, Tenon Hospital, AP-HP, Sorbonne Université, Paris, France; Department of Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP, Centre-Université de Paris, Paris, France
| | - S Richard
- Department of Medical Oncology, Tenon Hospital, AP-HP, Sorbonne Université, Paris, France
| | - C Crespel
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP, Centre-Université de Paris, Paris, France
| | - T Samaille
- Department of Radiation Oncology, Tenon Hospital, AP-HP, Sorbonne Université, Paris, France; Institut Curie, Department of Drug Development and Innovation (D3i), Paris & Saint-Cloud, France
| | - C Le Tourneau
- Institut Curie, INSERM U900 Research Unit, Saint-Cloud, France; Paris-Saclay University, Paris, France
| | - F Huguet
- Department of Radiation Oncology, Tenon Hospital, AP-HP, Sorbonne Université, Paris, France; Centre de Recherche Saint-Antoine, INSERM UMR_S 938, Saint-Antoine Hospital, Paris, France; Institut Universitaire de Cancérologie, Sorbonne Université, Paris, France.
| |
Collapse
|
3
|
Evin C, Eude Y, Jacob J, Jenny C, Bourdais R, Mathon B, Valery CA, Clausse E, Simon JM, Maingon P, Feuvret L. Hypofractionated postoperative stereotactic radiotherapy for large resected brain metastases. Cancer Radiother 2022; 27:87-95. [PMID: 36075831 DOI: 10.1016/j.canrad.2022.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 07/10/2022] [Accepted: 07/16/2022] [Indexed: 11/25/2022]
Abstract
PURPOSE The aim of the present retrospective study was to report outcomes after hypofractionated stereotactic radiotherapy (HSRT) for resected brain metastases (BM). PATIENTS AND METHODS We reviewed results of patients with resected BM treated with postoperative HSRT (3×7.7Gy to the prescription isodose 70%) between May 2013 and June 2020. Local control (LC), distant brain control (DBC), overall survival (OS), leptomeningeal disease relapse (LMDR), and radiation necrosis (RN) occurrence were reported. RESULTS Twenty-two patients with 23 brain cavities were included. Karnofsky Performance status (KPS) was≥70 in 77.3%. Median preoperative diameter was 37mm [21.0-75.0] and median planning target volume (PTV) was 23 cm3 [9.9-61.6]. Median time from surgery to SRT was 69 days [7-101] and 48% of patients had a local relapse on pre-SRT imaging. Median follow-up was 17.5 months [1.6-95.9]. One and two-year LC rates were 60.9 and 52.2% respectively. One and 2-year DBC rates were 45.5 and 40.9%. Median OS was 16.5 months. Four patients (18.2%) presented LMDR during follow-up. RN occurred in 6 patients (27.2%). Three factors were associated with OS: ECOG-PS (P=0.009), KPS (P=0.04), and cystic metastasis before surgery (P=0.037). Several factors were related to RN occurrence: PTV diameter and volume, Normal brain V21, V21 and V24 isodoses volumes. CONCLUSION HSRT is the most widely used scheme for larger brain cavities after surgery. The optimal dose and scheme remain to be defined as well as the optimal delay between postoperative SRT and surgery. Dose escalation may be necessary, especially in case of subtotal resection.
Collapse
Affiliation(s)
- C Evin
- Service d'oncologie radiothérapie, hôpitaux universitaires Pitié-Salpêtrière - Charles-Foix, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
| | - Y Eude
- Service d'ophtalmologie, Hôtel-Dieu, centre hospitalier universitaire de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes France
| | - J Jacob
- Service d'oncologie radiothérapie, hôpitaux universitaires Pitié-Salpêtrière - Charles-Foix, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - C Jenny
- Service d'oncologie radiothérapie, hôpitaux universitaires Pitié-Salpêtrière - Charles-Foix, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - R Bourdais
- Service d'oncologie radiothérapie, hôpitaux universitaires Pitié-Salpêtrière - Charles-Foix, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - B Mathon
- Service de neurochirurgie, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - C A Valery
- Service de neurochirurgie, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - E Clausse
- Service d'oncologie radiothérapie, hôpitaux universitaires Pitié-Salpêtrière - Charles-Foix, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - J M Simon
- Service d'oncologie radiothérapie, hôpitaux universitaires Pitié-Salpêtrière - Charles-Foix, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - P Maingon
- Service d'oncologie radiothérapie, hôpitaux universitaires Pitié-Salpêtrière - Charles-Foix, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - L Feuvret
- Service d'oncologie radiothérapie, hôpitaux universitaires Pitié-Salpêtrière - Charles-Foix, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| |
Collapse
|
4
|
Huguet F, Cerbai C, Ta MH, Sarrade T, Evin C, Aziez S, Rivin Del Campo E, Durand B, Loi M. Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy? Cancer Radiother 2022; 26:858-864. [PMID: 35987811 DOI: 10.1016/j.canrad.2022.06.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Accepted: 06/22/2022] [Indexed: 10/15/2022]
Abstract
Despite recent advances, the prognosis of pancreatic adenocarcinomas remains poor, even for patients with resectable tumors. For these latter, new approaches based on neoadjuvant treatment have been developed. Two components are used: chemotherapy and radiation therapy (RT). Indeed, pre-operative RT has many advantages in terms of efficacy and tolerance. It increases notably the chances of subsequent complete tumor resection. Several prospective trials are currently ongoing to clarify its place in the therapeutic arsenal. Another crucial question is to know which is the best RT technique: conventional normofractionated chemoradiotherapy or hypofrationated stereotactic body RT?
Collapse
Affiliation(s)
- F Huguet
- Service d'oncologie radiothérapie, hôpital Tenon, AP-HP, Sorbonne université, institut universitaire de cancérologie, 4, rue de la Chine, Paris, France; Inserm U938 Cancer Biology and Therapeutics, centre de recherche Saint-Antoine, 75012 Paris, France.
| | - C Cerbai
- Service d'oncologie radiothérapie, hôpital Tenon, AP-HP, Sorbonne université, institut universitaire de cancérologie, 4, rue de la Chine, Paris, France; Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - M H Ta
- Service d'oncologie radiothérapie, hôpital Tenon, AP-HP, Sorbonne université, institut universitaire de cancérologie, 4, rue de la Chine, Paris, France
| | - T Sarrade
- Service d'oncologie radiothérapie, hôpital Tenon, AP-HP, Sorbonne université, institut universitaire de cancérologie, 4, rue de la Chine, Paris, France
| | - C Evin
- Service d'oncologie radiothérapie, hôpital Tenon, AP-HP, Sorbonne université, institut universitaire de cancérologie, 4, rue de la Chine, Paris, France
| | - S Aziez
- Service d'oncologie radiothérapie, hôpital Tenon, AP-HP, Sorbonne université, institut universitaire de cancérologie, 4, rue de la Chine, Paris, France
| | - E Rivin Del Campo
- Service d'oncologie radiothérapie, hôpital Tenon, AP-HP, Sorbonne université, institut universitaire de cancérologie, 4, rue de la Chine, Paris, France
| | - B Durand
- Service d'oncologie radiothérapie, hôpital Tenon, AP-HP, Sorbonne université, institut universitaire de cancérologie, 4, rue de la Chine, Paris, France
| | - M Loi
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| |
Collapse
|
5
|
Evin C, Quéro L, Le Malicot K, Blanchet-Deverly S, François E, Buchalet C, Lemanski C, Baba Hamed N, Rivin del Campo E, Bauwens L, Pommier P, Lièvre A, Tougeron D, Macé V, Sergent G, Diaz O, Zucman D, Mornex F, Locher C, De la Rochefordière A, Vendrely V, Huguet F. MO-0226 Clinical outcomes of HIV-positive patients with anal cancer in the ANABASE multicentric cohort. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02328-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Evin C, Quéro L, Le Malicot K, Blanchet-Deverly S, François E, Buchalet C, Lemanski C, Baba Hamed N, Rivin Del Campo E, Bauwens L, Pommier P, Lièvre A, Tougeron D, Mace V, Sergent G, Diaz O, Zucman D, Mornex F, Locher C, de La Rochefordiere A, Vendrely V, Huguet F. Efficacité et toxicité de la (chimio)radiothérapie chez les patients séropositifs pour le VIH atteints d’un carcinome épidermoïde du canal anal, analyse en sous-groupe de la cohorte multicentrique Anabase. Cancer Radiother 2021. [DOI: 10.1016/j.canrad.2021.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
7
|
Evin C. Variations autour du thème - médecine et sciences. Med Sci (Paris) 1990. [DOI: 10.4267/10608/4112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
Evin C. [Nurses in hospital establishments]. Rev Infirm 1989; 39:46-7. [PMID: 2595183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|